Trials / Completed
CompletedNCT02582658
Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C - An Observational Study in Austria (REAL)
Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C -An Observational Study in Austria (REAL)
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 173 (actual)
- Sponsor
- AbbVie · Industry
- Sex
- All
- Age
- 18 Years – 99 Years
- Healthy volunteers
- Not accepted
Summary
The study seeks to provide evidence of the effectiveness and obtain patient reported outcome (PRO) and work productivity data of the interferon-free ABBVIE REGIMEN (ombitasvir/paritaprevir/ritonavir +/- dasabuvir) +/- Ribavirin (RBV) in chronic hepatitis C virus (HCV) infected participants in Austria.
Conditions
Timeline
- Start date
- 2015-10-06
- Primary completion
- 2017-01-12
- Completion
- 2017-01-12
- First posted
- 2015-10-21
- Last updated
- 2019-06-05
- Results posted
- 2019-06-05
Source: ClinicalTrials.gov record NCT02582658. Inclusion in this directory is not an endorsement.